Full-dose Atorvastatin Versus Conventional Medical Therapy After Non-ST-elevation Acute Myocardial Infarction in Patients With Advanced Non-revascularisable Coronary Artery Disease.

Trial Profile

Full-dose Atorvastatin Versus Conventional Medical Therapy After Non-ST-elevation Acute Myocardial Infarction in Patients With Advanced Non-revascularisable Coronary Artery Disease.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 31 Aug 2011

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Atrial fibrillation; Cardiovascular disorders; Coronary artery disease; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms APRIRE
  • Most Recent Events

    • 31 Aug 2011 Results of a secondary endpoint analysis (incidence of atrial fibrillation) presented at the ESC Congress 2011: Annual Congress of the European Society of Cardiology.
    • 07 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top